Literature DB >> 2380376

Immunoglobulin A antibodies to pertussis toxin and filamentous hemagglutinin in saliva from patients with pertussis.

G Zackrisson1, T Lagergård, B Trollfors, I Krantz.   

Abstract

Immunoglobulin A (IgA) antibodies against pertussis toxin (PT) and filamentous hemagglutinin (FHA) in 181 saliva samples obtained during various stages of pertussis from 112 patients were determined. Saliva samples obtained within 5 days after the onset of symptoms did not have detectable IgA antibodies against either of the two antigens. Of the samples obtained between 6 and 50 days after the onset of symptoms, 72% had antibodies against FHA but only 40% had antibodies against PT. With few exceptions, saliva samples obtained more than 50 days after the onset of symptoms contained antibodies against both antigens. In the 59 patients from whom paired saliva samples were obtained at intervals of 2 to 5 weeks, a significant increase in the geometric mean FHA antibody titers but not PT antibody titers occurred. However, increases that were fourfold or greater were observed against FHA in only 19 patients and against PT in 14 patients. Thus, IgA antibodies against FHA and PT in saliva develop during pertussis, and the importance of secretory IgA antibodies for protection against infection and disease should be investigated. Determination of these antibodies in paired saliva samples is, however, of little value for the laboratory diagnosis of pertussis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2380376      PMCID: PMC267977          DOI: 10.1128/jcm.28.7.1502-1505.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  21 in total

1.  Diagnosis of whooping cough--a comparison of culture, immunofluorescence and serology with ELISA.

Authors:  S Håkansson; C G Sundin; M Granström; B Gästrin
Journal:  Scand J Infect Dis       Date:  1984

2.  Serum antibody response to filamentous hemagglutinin in patients with clinical pertussis measured by an enzyme-linked immunosorbent assay.

Authors:  G Zackrisson; F Arminjon; I Krantz; T Lagergård; N Sigurs; J Taranger; B Trollfors
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

3.  Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells.

Authors:  E Tuomanen; A Weiss
Journal:  J Infect Dis       Date:  1985-07       Impact factor: 5.226

4.  Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

5.  Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase.

Authors:  R D Sekura; F Fish; C R Manclark; B Meade; Y L Zhang
Journal:  J Biol Chem       Date:  1983-12-10       Impact factor: 5.157

6.  Adherence of Bordetella pertussis to human respiratory epithelial cells.

Authors:  E I Tuomanen; J O Hendley
Journal:  J Infect Dis       Date:  1983-07       Impact factor: 5.226

7.  Serologic diagnosis of whooping cough by an enzyme-linked immunosorbent assay using fimbrial hemagglutinin as antigen.

Authors:  M Granström; G Granström; A Lindfors; P Askelöf
Journal:  J Infect Dis       Date:  1982-12       Impact factor: 5.226

8.  Adverse reactions and antibody responses to acellular pertussis vaccine.

Authors:  T Aoyama; S Hagiwara; Y Murase; T Kato; T Iwata
Journal:  J Pediatr       Date:  1986-12       Impact factor: 4.406

Review 9.  The concept of pertussis as a toxin-mediated disease.

Authors:  M Pittman
Journal:  Pediatr Infect Dis       Date:  1984 Sep-Oct

10.  A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children.

Authors:  K Lewis; J D Cherry; H J Holroyd; L R Baker; F E Dudenhoeffer; R G Robinson
Journal:  Am J Dis Child       Date:  1986-09
View more
  6 in total

1.  Immunoglobulin A-mediated protection against Bordetella pertussis infection.

Authors:  S M Hellwig; A B van Spriel; J F Schellekens; F R Mooi; J G van de Winkel
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

2.  Shelf life of prepared Bordet-Gengou and Regan-Lowe agar plates for isolation of Bordetella pertussis.

Authors:  G J Ruijs; T W Groenendijk; M Biever
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

3.  Induction of mucosal immune responses against a heterologous antigen fused to filamentous hemagglutinin after intranasal immunization with recombinant Bordetella pertussis.

Authors:  G Renauld-Mongénie; N Mielcarek; J Cornette; A M Schacht; A Capron; G Riveau; C Locht
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 4.  Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies.

Authors:  Seema Mattoo; James D Cherry
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

5.  Bordetella pertussis filamentous hemagglutinin enhances the immunogenicity of liposome-delivered antigen administered intranasally.

Authors:  O Poulain-Godefroy; N Mielcarek; N Ivanoff; F Remoué; A M Schacht; N Phillips; C Locht; A Capron; G Riveau
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

6.  Serum IgA responses against pertussis proteins in infected and Dutch wP or aP vaccinated children: an additional role in pertussis diagnostics.

Authors:  Lotte H Hendrikx; Kemal Öztürk; Lia G H de Rond; Sabine C de Greeff; Elisabeth A M Sanders; Guy A M Berbers; Anne-Marie Buisman
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.